Management and Clinical Outcomes of 37 Patients with Necrotizing Otitis Externa: Retrospective Review of a Standardized 6-Week Treatment Pathway

被引:2
|
作者
Dhariwal, Ankush [1 ]
Manjaly, Joseph G. [2 ]
Patel, Bhavesh [3 ]
Morris-Jones, Stephen [4 ]
David, Kate [5 ]
Khetarpal, Priya [6 ]
Beale, Tim [7 ]
Mehta, Nishchay [3 ]
Logan, Sarah [8 ]
机构
[1] North Middlesex Univ Hosp, IHIV Unit, London, England
[2] UCL, Ear Inst, NIHR UCLH BRC Deafness & Hearing Problems Theme, London, England
[3] Royal Natl ENT & Eastman Dent Hosp, Dept Otol, London, England
[4] Univ Coll London Hosp, Dept Clin Microbiol, London, England
[5] Royal London Hosp, Dept Infect, Barts Hlth NHS Trust, London, England
[6] Univ Hosp Lewisham, Dept Childrens Emergency, London, England
[7] Univ Coll London Hosp, Dept Radiol, London, England
[8] Univ Coll London Hosp, Hosp Trop Dis, Infect Div, London, England
来源
关键词
malignant otitis externa; necrotizing otitis externa; infection; UK;
D O I
10.5152/iao.2023.22637
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
BACKGROUND: Necrotizing otitis externa is an invasive infection, affecting older patients, with significant associated morbidity. Despite this, there are no randomized controlled trials that address management, and therefore, treatment approaches may vary considerably. We describe the management and outcomes of 37 patients managed using a multidisciplinary treatment pathway for necrotizing otitis externa over a 5-year period. The pathway is based on a standardized antibiotic regime of 3 weeks of intravenous ceftazidime plus oral ciprofloxacin, followed by a further 3 weeks of ciprofloxacin. METHODS: This is a retrospective review of all patients diagnosed with necrotizing otitis externa since the introduction of our pathway in 2016. We include data on patient demographics, comorbidities, microbiology, length of stay, and length of antimicrobial treatment. Outcome data, including mortality, relapse and treatment failure, and adverse effects of treatment, are presented. RESULTS: The median age of our patients was 82 years. About 54% of patients had diabetes mellitus or another cause of immunocompromise. Pseudomonas aeruginosa was isolated in 68%. The median duration of inpatient stay was 9 days, and median treatment duration was 6 weeks. Of 37 patients, 32 were cured (86%), and of the remaining 5 patients, there were 2 mortalities unrelated to necrotizing otitis externa and 3 patients with recurrent infections due to anatomical abnormalities. CONCLUSION: We note favorable treatment outcomes when using a standardized multidisciplinary pathway and a 6-week course of antibiotic therapy.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 49 条
  • [31] Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study
    Kotsakis, Athanasios
    Ardavanis, Alexandros
    Koumakis, Georgios
    Samantas, Epameinondas
    Psyrri, Amanta
    Papadimitriou, Christos
    BMC CANCER, 2019, 19 (1)
  • [32] Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study
    Athanasios Kotsakis
    Alexandros Ardavanis
    Georgios Koumakis
    Epameinondas Samantas
    Amanta Psyrri
    Christos Papadimitriou
    BMC Cancer, 19
  • [33] Hip preserving surgery with concentrated autologous bone marrow aspirate transplantation for the treatment of asymptomatic osteonecrosis of the femoral head: retrospective review of clinical and radiological outcomes at 6 years postoperatively
    Tomaru, Yohei
    Yoshioka, Tomokazu
    Sugaya, Hisashi
    Aoto, Katsuya
    Wada, Hiroshi
    Akaogi, Hiroshi
    Yamazaki, Masashi
    Mishima, Hajime
    BMC MUSCULOSKELETAL DISORDERS, 2017, 18
  • [34] Hip preserving surgery with concentrated autologous bone marrow aspirate transplantation for the treatment of asymptomatic osteonecrosis of the femoral head: retrospective review of clinical and radiological outcomes at 6 years postoperatively
    Yohei Tomaru
    Tomokazu Yoshioka
    Hisashi Sugaya
    Katsuya Aoto
    Hiroshi Wada
    Hiroshi Akaogi
    Masashi Yamazaki
    Hajime Mishima
    BMC Musculoskeletal Disorders, 18
  • [35] A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments
    Wagner, Michael J.
    Amodu, Leo Ismaila
    Duh, Mei Sheng
    Korves, Caroline
    Solleza, Franco
    Manson, Stephanie C.
    Diaz, Jose
    Neary, Maureen P.
    Demetri, George D.
    BMC CANCER, 2015, 15
  • [36] A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments
    Michael J Wagner
    Leo Ismaila Amodu
    Mei Sheng Duh
    Caroline Korves
    Franco Solleza
    Stephanie C Manson
    José Diaz
    Maureen P Neary
    George D Demetri
    BMC Cancer, 15
  • [37] Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment-A retrospective chart review
    Vockley, Jerry
    Marsden, Deborah
    McCracken, Elizabeth
    DeWard, Stephanie
    Barone, Amanda
    Hsu, Kristen
    Kakkis, Emil
    MOLECULAR GENETICS AND METABOLISM, 2015, 116 (1-2) : 53 - 60
  • [38] A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
    Nicolini, Franck-Emmanuel
    Huguet, Francoise
    Huynh, Lynn
    Xu, Churong
    Bouvier, Christophe
    Yocolly, Aurore
    Etienne, Gabriel
    CANCERS, 2023, 15 (16)
  • [39] Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe
    Zhang, Jingchuan
    Kelkar, Sneha S.
    Prabhu, Vimalanand S.
    Qiao, Yao
    Grall, Veronique
    Miles, Nicola
    Marth, Christian
    BMJ OPEN, 2024, 14 (04):
  • [40] Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review
    Bang, Soo-Mee
    Kang, Ka-Won
    Song, Ik-Chan
    Llamas, Cynthia
    Duan, Yinghui
    Jeong, Ji-Young
    Lee, Je-Hwan
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (44)